These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. Chuah C; Koh LP; Numbenjapon T; Zang DY; Ong KH; Do YR; Ohkura M; Ono C; Viqueira A; Cortes JE; Brümmendorf TH Int J Hematol; 2021 Jul; 114(1):65-78. PubMed ID: 33851349 [TBL] [Abstract][Full Text] [Related]
25. Successful desensitization to fixed drug eruption: the presence of CD25+CD4+ T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization. Teraki Y; Shiohara T Dermatology; 2004; 209(1):29-32. PubMed ID: 15237264 [TBL] [Abstract][Full Text] [Related]
26. Non-pigmenting cutaneous-mucosal fixed drug eruption due to piroxicam. Montoro J; Díaz M; Genís C; Lozano A; Bertomeu F Allergol Immunopathol (Madr); 2003; 31(1):53-5. PubMed ID: 12573211 [TBL] [Abstract][Full Text] [Related]
27. Bosutinib - related pleural effusion in patients with chronic myeloid leukemia. Yüzbaşıoğlu MB; Eşkazan AE Expert Opin Drug Saf; 2021 Apr; 20(4):379-381. PubMed ID: 33339467 [No Abstract] [Full Text] [Related]
28. The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use. Hanaizi Z; Unkrig C; Enzmann H; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F Oncologist; 2014 Apr; 19(4):421-5. PubMed ID: 24668331 [TBL] [Abstract][Full Text] [Related]
29. Nonpigmenting fixed drug eruption as a possible abortive variant of toxic epidermal necrolysis: immunohistochemical and serum cytokine analyses. Mizukawa Y; Shiohara T Clin Exp Dermatol; 2010 Jul; 35(5):493-7. PubMed ID: 19874369 [TBL] [Abstract][Full Text] [Related]
30. Postcoital fixed drug eruption in a man sensitive to trimethoprim-sulphamethoxazole. Gruber F; Stasić A; Lenković M; Brajac I Clin Exp Dermatol; 1997 May; 22(3):144-5. PubMed ID: 9425695 [TBL] [Abstract][Full Text] [Related]
31. Neutrophilic fixed drug eruption, a histopathologic variant or an expected finding?-A report of two cases and review of the literature. Theroux Z; Gardner J; Ortiz E; Kosik G; Junkins-Hopkins J J Cutan Pathol; 2023 Oct; 50(10):884-889. PubMed ID: 37403191 [TBL] [Abstract][Full Text] [Related]
32. Fixed drug eruption: state of the art. Ozkaya E J Dtsch Dermatol Ges; 2008 Mar; 6(3):181-8. PubMed ID: 18076661 [TBL] [Abstract][Full Text] [Related]
33. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Gambacorti-Passerini C; Cortes JE; Lipton JH; Dmoszynska A; Wong RS; Rossiev V; Pavlov D; Gogat Marchant K; Duvillié L; Khattry N; Kantarjian HM; Brümmendorf TH Am J Hematol; 2014 Oct; 89(10):947-53. PubMed ID: 24944159 [TBL] [Abstract][Full Text] [Related]
35. A Review of Fixed Drug Eruption with a Special Focus on Generalized Bullous Fixed Drug Eruption. Anderson HJ; Lee JB Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577848 [TBL] [Abstract][Full Text] [Related]
37. Fixed drug eruption to ibuprofen in daughter and father. Al Aboud K; Ramesh V; Al Hawsawi K J Drugs Dermatol; 2003 Dec; 2(6):658-9. PubMed ID: 14711146 [TBL] [Abstract][Full Text] [Related]
38. Peculiar unilateral fixed drug eruption of the breast. Li H; Wiederkehr M; Rao Bk; Samady JA; Gardner B; Lambert WC; Schwartz RA Int J Dermatol; 2002 Feb; 41(2):96-8. PubMed ID: 11982645 [TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. García-Gutiérrez V; Milojkovic D; Hernandez-Boluda JC; Claudiani S; Martin Mateos ML; Casado-Montero LF; González G; Jimenez-Velasco A; Boque C; Martinez-Trillos A; Vázquez IM; Payer ÁR; Senín A; Amustio Díez E; García AB; Carrascosa GB; Ortí G; Ruiz BC; Fernández MÁ; Del Carmen García Garay M; Giraldo P; Guinea JM; De Las Heras Rodríguez N; Hernán N; Pérez AI; Piris-Villaespesa M; Lorenzo JLL; Martí-Tutusaus JMM; Vallansot RO; Ortega Rivas F; Puerta JM; Ramirez MJ; Romero E; Romo A; Rosell A; Saavedra SS; Sebrango A; Tallon J; Valencia S; Portero A; Steegmann JL; Ann Hematol; 2019 Feb; 98(2):321-330. PubMed ID: 30446802 [TBL] [Abstract][Full Text] [Related]
40. Fixed drug eruption from piroxicam. Cuerda Galindo E; Goday Buján JJ; García Silva JM; Martínez W; Verea Hernando M; Fonseca E J Eur Acad Dermatol Venereol; 2004 Sep; 18(5):586-7. PubMed ID: 15324401 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]